PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35395766-10	2022	CONCLUSIONS: Dynamic changes of ALP (non-rise) and LDH (normalization) under therapy with Enzalutamide may be associated with clinical benefit, better PFS, and OS in patients with bmCRPC who do not show a PSA decline.	enzalutamide	90-102	alkaline phosphatase, placental	Homo sapiens	32-35	
30274641-8	2018	CONCLUSION: Enzalutamide is less effective in patients with metastatic chemotherapy-naive CRPC with Gleason scores >= 9, visceral metastasis, high NLR, and high ALP.	enzalutamide	12-24	alkaline phosphatase, placental	Homo sapiens	164-167	
34804841-0	2021	ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.	enzalutamide	119-131	alkaline phosphatase, placental	Homo sapiens	0-3